1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Other Hematological Disorders – Pipeline Review, H1 2013

Other Hematological Disorders – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 49 pages

Other Hematological Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Other Hematological Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Hematological Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Hematological Disorders. Other Hematological Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Hematological Disorders.
- A review of the Other Hematological Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Hematological Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Hematological Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Hematological Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Other Hematological Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Other Hematological Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Other Hematological Disorders 8
Other Hematological Disorders Therapeutics under Development by Companies 10
Other Hematological Disorders Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Other Hematological Disorders Therapeutics - Products under Development by Companies 16
Other Hematological Disorders Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Other Hematological Disorders Therapeutics Development 18
Mitsubishi Tanabe Pharma Corporation 18
Regado Biosciences. 19
Embryome Sciences, Inc. 20
Other Hematological Disorders - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 28
REG-Anti Platelet Program - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
GB-1057 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
nitric oxide - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
rituximab - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
carvedilol - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
vinblastine sulfate + methotrexate + 6-mercaptopurine - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
REG-3 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Vascular Program - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Interleukin-7 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Erythropoietin Encoding mRNA - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Other Hematological Disorders Therapeutics - Drug Profile Updates 40
Other Hematological Disorders Therapeutics - Dormant Products 41
Other Hematological Disorders - Product Development Milestones 42
Featured News and Press Releases 42
Jul 07, 2011: CorMedix Submits Design Dossier For Neutrolin To Start European Approval Process 42
Jun 29, 2011: Kyowa Hakko Kirin Initiates Phase III Clinical Study Of KW-3357 In Japan 42
Jun 01, 2011: S*BIO's SB1518 Alleviates MF-Associated Splenomegaly And Shows No Myelosuppression And No Exacerbation Of Cytopenias 43
Jan 31, 2011: AMT Receives EUR1.1 Million Funding For Acute Intermittent Porphyria Gene Therapy 43
Jan 19, 2011: Geron Initiates Phase II Clinical Trial Of Imetelstat In Patients With Essential Thrombocythemia 44
Aug 12, 2010: Neumedicines Receives $2.5 Million From HHS/BARDA After Successful Non-Human Primate Studies to Further Advance HemaMax As a Radiation Countermeasure 45
Jun 16, 2010: Relypsa Initiates Open-Label Phase II Clinical Study Of RLY5016 For Management Of Hyperkalemia 45
Jun 02, 2010: Alexion Accelerates Plans To Launch Soliris In Japan 46
Jun 01, 2010: LLS And Onconova Form Partnership To Advance Clinical Development Of ESTYBON In High Risk MDS Patients 46
Apr 20, 2010: Alexion Completes Enrollment in All Four Clinical Trials of Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49



List of Tables

Number of Products Under Development for Other Hematological Disorders, H1 2013 8
Products under Development for Other Hematological Disorders - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 17
Mitsubishi Tanabe Pharma Corporation, H1 2013 18
Regado Biosciences., H1 2013 19
Embryome Sciences, Inc., H1 2013 20
Assessment by Monotherapy Products, H1 2013 21
Assessment by Combination Products, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 27
Other Hematological Disorders Therapeutics - Drug Profile Updates 40
Other Hematological Disorders Therapeutics - Dormant Products 41



List of Figures

Number of Products under Development for Other Hematological Disorders, H1 2013 8
Products under Development for Other Hematological Disorders - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Discovery and Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 21
Assessment by Combination Products, H1 2013 22
Assessment by Route of Administration, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Molecule Type, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016 ...

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2016

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Transmembrane Prolyl 4 Hydroxylase ...


Download Unlimited Documents from Trusted Public Sources

Procter - Company Report, August 2016

  • August 2016
    5 pages
  • Pathology  

    Cancer  

  • United States  

    Australia  

View report >

Memorial Sloan Kettering Cancer Center - Company Report, July 2016

  • July 2016
    8 pages
  • Medical Center  

    Oncology  

  • United States  

    North America  

View report >

Memorial Sloan Kettering Cancer Center - Company Report, July 2016

  • July 2016
    7 pages
  • Cancer  

    Medical Center  

    Oncology  

  • United States  

    North America  

View report >

Related Market Segments :

Blood Disease

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.